Shots:

• The approval is based on data from two P-III studies i.e SELECT-PsA 1 & 2 evaluating the safety & efficacy of Rinvoq vs PBO in 2-000+ patients with active PsA who have had an inadequate response to methotrexate or other DMARDs
• The studies met their 1EPs of ACR20 response @12wks.- Rinvoq (15mg) showed non-inferiority to adalimumab for ACR20 response- improvements in HAQ-DI & skin symptoms (PASI 75)- a greater proportion of patients achieved minimal disease activity
• The safety profile was consistent with previously reported data in RA with no new safety risks observed. Rinvoq is a selective & reversible JAK inhibitor that interferes with the JAK-STAT signaling pathway

  | Ref: AbbVie | Image: AbbVie